Hydron;methyl 3-(1-phenylethyl)imidazole-4-carboxylate;chloride | 36557-22-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Hydron;methyl 3-(1-phenylethyl)imidazole-4-carboxylate;chloride
• CAS: 36557-22-9
• 化学式: C13H15ClN2O2
• 分子量: 266.72
• InChiKey: NZEDTZKNEKPBGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  44.1
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• A polypeptide growth factor from milk
  申请人：CIBA-GEIGY AG

  公开号：EP0313515A1

  公开（公告）日：1989-04-26

  A Milk Growth Factor (MGF) obtainable from milk, methods for its isola­tion and purification from milk or milk products, pharmaceutical compo­sitions, food compositions and cell growth media comprising the factor and the uses thereof for treating trauma in mammals, suppressing the immune response, treating cancer, stimulating growth of mammals and cell cultures.

  一种可从牛奶中获得的牛奶生长因子（MGF），从牛奶或牛奶产品中分离和纯化该因子的方法，包含该因子的药物组合物、食品组合物和细胞生长培养基，以及其在治疗哺乳动物创伤、抑制免疫反应、治疗癌症、刺激哺乳动物和细胞培养物生长方面的用途。
• Use of TNF-alpha inhibitors for treating nerve root injury
  申请人：Sciaticon AB

  公开号：EP1941872A1

  公开（公告）日：2008-07-09

  The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-α comprising an effective amount of a TNF-α inhibitor, as well as methods for treatment of such disorders, and the use of TNF-α inhibitors in the preparation of pharmaceutical compositions for such treatment.

  本发明涉及治疗由TNF-α释放引起的脊柱疾病的药物组合物，其中包含有效量的TNF-α抑制剂，还涉及治疗此类疾病的方法，以及在制备用于此类治疗的药物组合物时使用TNF-α抑制剂。
• ANAESTHETIC SOLUTION AND METHOD OF USE THEREOF FOR ANAESTHETISING, STUNNING AND SLAUGHTERING FISH
  申请人：Universidad Politecnica de Cartagena

  公开号：EP3424536A1

  公开（公告）日：2019-01-09

  This invention relates to an anesthetic solution comprising a natural anesthetic agent (clove essential oil, isoeugenol, and/or eugenol), nanoencapsulated in food-grade β-cyclodextrins, with a moisture content not greater than 14%, forming a water-soluble inclusion complex, wherein the proportion of the natural anesthetic in the inclusion complex is comprised between 5 and 30%, the proportion of β-cyclodextrins is comprised between 70 and 95% of the total mass of the complex, in which the anesthetic agent is formulated in freshwater, seawater, ice slurry, or water with crushed ice, at a concentration comprised between 5 and 60 mg/kg of water. Methods developed for anesthetizing, stunning, and/or slaughtering fish based on using the solution of the invention are likewise contemplated.

  本发明涉及一种麻醉溶液，该溶液由天然麻醉剂（丁香精油、异丁香酚和/或丁香酚）纳米包囊在食品级β-环糊精中，水分含量不大于 14%，形成水溶性包合物、其中天然麻醉剂在包合物中的比例为 5%至 30%，β-环糊精的比例为包合物总质量的 70%至 95%，其中麻醉剂配制在淡水、海水、冰浆或加碎冰的水中，浓度为 5 至 60 毫克/千克水。在使用本发明溶液的基础上开发的用于麻醉、电击和/或屠宰鱼类的方法也同样可以考虑。
• Use of certain drugs for treating nerve root injury
  申请人：——

  公开号：US20010027199A1

  公开（公告）日：2001-10-04

  The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-&agr; comprising an effective amount of a TNF-&agr; inhibitor, as well as a method for treatment of such disorders, and the use of TNF-&agr; inhibitors in the preparation of pharmaceutical compositions for such treatment.

  本发明涉及治疗由TNF-&agr;释放引起的脊柱疾病的药物组合物，其中包含有效量的TNF-&agr;抑制剂，还涉及治疗此类疾病的方法，以及在制备用于此类治疗的药物组合物中使用TNF-&agr;抑制剂。
• Vaccines and agents for inducing immunity against rickettsial diseases, and associated preventative therapy
  申请人：——

  公开号：US20030165526A1

  公开（公告）日：2003-09-04

  The use of the 17 kDa outer surface lipoprotein (OspA) of Piscirickettsia salmonis, or its homologues, as the basis of, or part thereof, a recombinant vaccine for salmonid rickettsial septicaemia and other rickettsial diseases is disclosed. Surface antigens of the bacterial pathogen P. salmonis are characterized and an immunoreactive antigen, namely the 17 kDa outer surface lipoprotein OspA of P. salmonis, as well as the nucleic acid segment that encodes the OspA immunoreactive antigen, is identified and characterized. Diagnostic techniques including the use of hybridization probes and primers as well as the production of specific antigens and antibodies that may be used in immunization techniques for inducing immunity against P. salmonis and other rickettsial diseases are disclosed, as are the development of recombinant vaccines for SRS and other rickettsial diseases based on the 17 kDa lipoprotein OspA. Augmentation of protective immunity by the inclusion of promiscuous T lymphocyte epitopes (TCE's) in fusion protein constructs in salmonids and to the use of bacterial protein inclusion bodies as a source of the protective immunogen is also disclosed.

  利用鲑鱼鱼盘立克次体的 17 kDa 外表面脂蛋白 (OspA) 或其同源物，作为鲑鱼立克次体败血症重组疫苗的基础或其一部分、 或其同源物，作为鲑鱼立克次体败血症和其他立克次体疾病重组疫苗的基础或其一部分。细菌病原体的表面抗原 鲑鱼 的 17 kDa 外表面脂蛋白 OspA 具有免疫活性。 沙门氏菌的 以及编码 OspA 免疫活性抗原的核酸片段。诊断技术包括杂交探针和引物的使用，以及特异性抗原和抗体的生产，这些抗原和抗体可用于免疫技术，以诱导对鲑鱼弧菌的免疫。 沙门氏菌 还公开了基于 17 kDa 脂蛋白 OspA 的 SRS 和其他立克次体疾病重组疫苗的开发。此外，还披露了通过在鲑鱼融合蛋白构建体中加入杂乱的 T 淋巴细胞表位（TCE）来增强保护性免疫，以及使用细菌蛋白包涵体作为保护性免疫原的来源。